Free Newsletter
Zyprexa reps told to "neutralize" diabetes link
Documents unsealed in Alaska show that Eli Lilly sales reps touting Zyprexa were told to "neutralize the diabetes/hyperglycemia issue" that arose when doctors started pointing out that the drug might lead to the disease. "The competition wins when we are distracted into talking about diabetes," the documents state. Lilly says it hasn't downplayed Zyprexa's risks and that the documents are "a tiny fraction" of those provided as part of the Alaska lawsuit over the drug. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: